Osteoarticular InfectionsIntensive Care PatientsProsthetic Joint Infection
Investigational drug(s) / intervention(s)
Global cohort
Global cohort: All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.
Study summary
This is an observational, retrospective, multicenter study based on the use of demographic, clinical and biological data from deceased patients admitted between 2018 and 2022 to critical care with a principal or associated diagnosis of joint prosthesis infection.
Data from this study will be combined with that from the OASIS study (APHP241174/ ID-RCB: 2024-A01769-38) concerning osteoarticular sepsis on prosthetic material in critical care of living patients.
The aim of this study is to improve our knowledge of the profile, care trajectories and outcomes of patients hospitalized in critical care in the context of osteoarticular material sepsis.
The results of the study could help identify at-risk populations and improve management strategies for patients with osteoarticular sepsis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient aged 18 years or older.
* Hospitalization in critical care (intensive care unit or continuing care unit) between 2018 and 2022, lasting at least 48 hours, with a prosthetic joint infection (hip, knee, or shoulder prosthesis infection) as the primary or associated diagnosis.
* Deceased patient who had not refused data processing.
Exclusion Criteria:
* Infection involving osteosynthesis material
* Infection involving spinal instrumentation
* Patient with multiple infected prostheses
* Recurrence of prosthetic infection with the same microorganism as a previous episode
* Patient under legal protection
* Pregnant or breastfeeding patient
* Patient deprived of liberty
Primary outcome measure(s)
Epidemiological description of deceased patients — 2 years Demographic data, medical history, history of Periprosthetic Joint Infection (timing, diagnosis, surgery, antibiotics), data in intensive care unit (leng of stay, organ failure, drugs and mechanical support, biological data) and outcome (time of death within 2 years after admission to Intensive Care Units).
Trial sites (1)
Facility
City
Region
Status
Hôpital Lariboisière
Paris
France
Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
